IN THE CLAIMS:

New claims 12 through 22 are presented below. This listing of claims will replace all prior versions and listings of claims in the application. All claim amendments and cancellations are made without prejudice or disclaimer. Please amend the claims as follows:

1. (Currently amended) A method of treating a patient suffering from, or at risk of suffering from a chronic coronary syndrome, the method comprising:

producing ~~Use of~~ erythropoietin (EPO), or derivative or functional analogue thereof, ~~that has been produced~~ in a host cell expressing at least the E1A protein of an adenovirus;~~,~~

~~for the preparation of~~ preparing a medicament comprising said EPO, or derivative or functional analogue thereof, for the preventive and/or curative treatment of a patient suffering from, or at risk of suffering from a chronic coronary syndrome; and

administering said medicament to said patient.

2. (Currently amended) The method ~~Use~~ according to claim 1, wherein said host cell is derived from a PER.C6 cell.

3. (Currently amended) The method ~~Use~~ according to claim 1 ~~or claim 2~~, wherein said coronary syndrome is chronic cardiac failure.

4. (Currently amended) The method ~~Use~~ according to claim 1 ~~or claim 2~~, wherein said coronary syndrome is chronic myocardial ischemia.

5. (Currently amended) The method ~~Use~~ according to ~~any one of the preceding claims~~ claim 1, wherein said patient is non-anemic.

6. (Currently amended) A pharmaceutical preparation comprising erythropoietin (EPO), or derivative or functional analogue thereof, that has been produced in a host cell

expressing at least the E1A protein of an adenovirus, and one or more compounds selected from the group consisting of ~~statines~~ statins and Angiotensin Converting Enzyme-inhibitors (ACE-inhibitors).

7. (Currently amended) A method ~~Method~~ for treating a patient suffering from, or at risk of suffering from a chronic coronary syndrome, said method comprising: ~~a step of~~ administering erythropoietin (EPO), or derivative or functional analogue thereof, that has been produced in a host cell expressing at least the E1A protein of an adenovirus.

8. (Currently amended) The method ~~Method~~ according to claim 7, wherein said host cell is derived from a PER.C6 cell.

9. (Currently amended) The method ~~Method~~ according to claim 7 ~~or claim 8~~, wherein said coronary syndrome is chronic cardiac failure.

10. (Currently amended) The method ~~Method~~ according to claim 7 ~~or claim 8~~, wherein said coronary syndrome is chronic myocardial ischemia.

11. (Currently amended) The method ~~Method~~ according to ~~any one of claims 7-10~~ claim 7, wherein said patient is non-anemic.

12 (New) A method of treating a subject suffering from, or at risk of suffering from, a chronic coronary syndrome, the method comprising:

administering an active ingredient selected from the group consisting of erythropoietin, a derivative of erythropoietin, and a functional analogue of erythropoietin, to the subject;

inducing decreased undesirable side effects in the subject, wherein the active ingredient is a peptide produced by a process comprising:

providing a host cell expressing at least the E1A protein of an adenovirus;

culturing the host cell under suitable conditions to produce the active ingredient in the host cell; and

isolating the active ingredient from the host cell or culture media.

13. (New) The method according to claim 12, wherein the host cell is derived from a PER.C6™ cell containing an exogenous nucleic acid sequence encoding the active ingredient.

14. (New) The method according to claim 12, wherein the coronary syndrome is chronic cardiac failure.

15. (New) The method according to claim 12, wherein the coronary syndrome is chronic myocardial ischemia.

16. (New) The method according to claim 12, wherein the subject is non-anemic.

17. (New) The method according to claim 12, wherein the active ingredient is erythropoietin.

18. (New) The method according to claim 17, wherein the subject has an initial hemoglobin level between 6.5 mmol/L and 8.7 mmol/L.

19. (New) The method according to claim 17, wherein administering erythropoietin to the subject comprises inducing less of an increase in hematocrit values as determined by comparison to an EPREX® erythropoietin preparation.

20. (New) A method of treating a subject suffering from, or at risk of suffering from, a chronic coronary syndrome, the method comprising:

administering to the subject at least one compound selected from the group consisting of a statin and an Angiotensin-Converting Enzyme inhibitor; and

co-administering erythropoietin (EPO) to the subject, wherein the EPO is produced by the process comprising:

expressing EPO in a host cell expressing at least the E1A protein of an adenovirus; and

isolating the erythropoietin from the host cell or culture media.

21. (New) The method according to claim 20, wherein the statin is Lovastatin.

22. (New) The pharmaceutical preparation of claim 20, wherein the statin is simvastatin.